Rising prostate-specific antigen after primary prostate cancer therapy.
about
Role of Dose Intensification for Salvage Radiation Therapy after Radical ProstatectomyTherapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysisEpidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancerProstate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy.Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study.Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.Postoperative radiotherapy after radical prostatectomy: indications and open questionsThe incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience.MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression.Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy.Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate.Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice.Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.KLK-targeted Therapies for Prostate Cancer.Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.Identification of miR-30d as a novel prognostic maker of prostate cancer.Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml.Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.Altered expression patterns of syndecan-1 and -2 predict biochemical recurrence in prostate cancer.Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes.
P2860
Q26765872-80BF8AAD-1444-4BDB-9B89-20023DA601E9Q28533222-48ADFA99-899D-483E-8FC4-9BA2227468DBQ28535425-3B00E332-EDE4-42E1-9B4E-1491926BA286Q33893647-1685E7F2-8CFA-46BD-97CB-416F346E0B0EQ33896203-96F52D3F-594D-444B-8FA8-E4FCC533D037Q34325482-B99116BD-D420-4AF2-801E-96DA3D92C4ABQ34794205-01BC1EEC-8E8F-4757-B49D-26A41B676330Q35319604-98A759B3-1799-41A1-9919-F8F094A404B3Q35685540-F91E34C0-39E6-40A1-9FA5-93F37CBB9B3CQ35863963-AE6E9BC2-8194-40FB-BED7-C90CF78E65E0Q36290824-957FCD56-4313-4D48-9329-CBAA296F56B7Q36301750-17E684CC-8DA9-4B38-A1F9-21E365BD87EFQ36338964-60493902-CDF0-4B53-A399-2A92C5622CEBQ37437499-AE643441-8FD7-453B-A0C1-167C43FE3F29Q37668198-A8F0E8BF-C6A0-4BCE-94C7-5EADBB9F38EDQ38260716-5A5889B1-F161-417A-BA3D-110F7C69BDD1Q38705877-AC11EAF4-2A2A-472A-820C-9B041D2A5EA9Q38898477-593A1FCE-C507-4A4D-8DBF-4EB5EA66091DQ38967486-AD26F444-2737-4D78-8F9D-CA7ACB545ED6Q38982759-CCAC712E-CCA7-45AB-AEC5-C5CC0A6F47F4Q39227897-3A9E34BE-4316-4111-A33C-B00BA627C661Q39248297-F93520F2-65AF-490C-B5BA-B91942C4256AQ39675735-8190EA33-23A9-4321-808D-CC0AE85B8624Q39987660-968223B2-8F42-41FA-900D-438EAB1FB5D3Q41336766-337055D3-1B3E-426E-946B-A2D3A7FEF014Q42141004-87AC13AE-C380-413C-8C39-9280A393C265Q47589926-401B3ECD-896A-43D4-8266-9D8D34DB2FD4Q55660188-57585F38-EB94-40BE-993E-19718EDCECB3
P2860
Rising prostate-specific antigen after primary prostate cancer therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Rising prostate-specific antigen after primary prostate cancer therapy.
@ast
Rising prostate-specific antigen after primary prostate cancer therapy.
@en
type
label
Rising prostate-specific antigen after primary prostate cancer therapy.
@ast
Rising prostate-specific antigen after primary prostate cancer therapy.
@en
prefLabel
Rising prostate-specific antigen after primary prostate cancer therapy.
@ast
Rising prostate-specific antigen after primary prostate cancer therapy.
@en
P2860
P356
P1476
Rising prostate-specific antigen after primary prostate cancer therapy.
@en
P2093
John F Ward
Judd W Moul
P2860
P2888
P304
P356
10.1038/NCPURO0145
P407
P577
2005-04-01T00:00:00Z
P6179
1005469264